Viltolarsen
CAS 2055732-84-6 2 FDA-DMF suppliersNucleotide
Overview
Viltolarsen is an antisense oligonucleotide used in the treatment of Duchenne muscular dystrophy in patients amenable to exon 53 skipping. It promotes dystrophin production by skipping exon 53, helping to slow disease progression.
Patent & exclusivity (US)
Per the FDA Orange Book (1 approved US product), the latest listed US patent on Viltolarsen expires 2 Apr 2034 and exclusivity 11 Aug 2027. Generic API sourcing typically opens up once these lapse.
Therapeutic areas
Neuromuscular Disorders
Ready to Accelerate Your
Discovery Workflow?
Find, vet, and source drug-manufacturing partners faster — with FDA compliance screening built in. Start free for 14 days.